{"entity":{"id":"2004","kind":"year","name":"2004 in oncology","aka":["2004"],"tldr":"Everything OnCo dates to 2004: 129 entries, 28 landmarks, 26 papers listed on people's pages, 23 papers and 19 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"129 dated entries in OnCo fall in 2004: 28 landmarks, 26 papers listed on people's pages, 23 papers, 19 approvals, 10 trials reported, 8 companies founded, 5 journals founded, 5 regulatory events, 3 technologies and 2 laws and regulations.\n\nOf those, 1 to the day, 3 to the month and 125 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2003","2005"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2004,"events":[{"group":"approval","date":"2004","precision":"year","title":"Anagrelide approved in EU","note":"Elevated platelet counts in at-risk essential thrombocythaemia intolerant of or inadequately controlled by current therapy (Xagrid)","from":"anagrelide","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Azacitidine approved in US","note":"Myelodysplastic syndromes","from":"azacitidine","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Bevacizumab approved in US","note":"First-line metastatic colorectal cancer with 5-FU chemotherapy","from":"bevacizumab","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Cetuximab approved in EU","note":"EGFR-expressing metastatic colorectal cancer; later restricted to RAS wild-type. Erbitux marketing authorisation issued 29 June 2004.","from":"cetuximab","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Cetuximab approved in US","note":"EGFR-expressing metastatic colorectal cancer (later restricted to RAS wild-type)","from":"cetuximab","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Cinacalcet approved in US","note":"Hypercalcaemia in patients with parathyroid carcinoma; secondary hyperparathyroidism on dialysis; primary hyperparathyroidism when surgery is not possible","from":"cinacalcet","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Cladribine approved in EU","note":"Hairy cell leukaemia (Litak, subcutaneous)","from":"cladribine","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Clofarabine approved in US","note":"Relapsed or refractory ALL in patients aged 1 to 21 after at least two prior regimens (accelerated)","from":"clofarabine","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Docetaxel approved in US","note":"Metastatic CRPC (with prednisone)","from":"docetaxel","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Erlotinib approved in US","note":"Locally advanced/metastatic NSCLC after chemotherapy","from":"erlotinib","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"FOLFOX (5-FU, leucovorin, oxaliplatin) approved in US","note":"Adjuvant stage III colon cancer (oxaliplatin, MOSAIC)","from":"folfox","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Gemcitabine approved in US","note":"Metastatic breast cancer with paclitaxel","from":"gemcitabine","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Ibritumomab tiuxetan approved in EU","note":"Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008","from":"ibritumomab-tiuxetan","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Imiquimod approved in US","note":"Actinic keratosis; superficial basal cell carcinoma in immunocompetent adults","from":"imiquimod","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Methyl aminolevulinate approved in US","note":"Thin non-hyperkeratotic actinic keratoses of the face and scalp, with red light photodynamic therapy","from":"methyl-aminolevulinate","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Mitotane approved in EU","note":"Advanced adrenocortical carcinoma","from":"mitotane","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Oxaliplatin approved in US","note":"Adjuvant stage III colon cancer","from":"oxaliplatin","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Palifermin approved in US","note":"Reduction of severe oral mucositis in haematological malignancies with myelotoxic therapy and autologous stem cell support","from":"palifermin","refs":[]},{"group":"approval","date":"2004","precision":"year","title":"Pemetrexed approved in US","note":"Unresectable pleural mesothelioma with cisplatin","from":"pemetrexed","refs":[]},{"group":"company","date":"2004","precision":"year","title":"Amgen Ventures founded","note":"Thousand Oaks, CA","from":"amgen-ventures","refs":[]},{"group":"company","date":"2004","precision":"year","title":"Bellicum Pharmaceuticals founded","note":"Houston, TX","from":"bellicum","refs":[]},{"group":"company","date":"2004","precision":"year","title":"C-RAD founded","note":"Uppsala","from":"c-rad","refs":[]},{"group":"company","date":"2004","precision":"year","title":"Khosla Ventures founded","note":"Menlo Park, CA","from":"khosla-ventures","refs":[]},{"group":"company","date":"2004","precision":"year","title":"Molecular Partners founded","note":"Zurich","from":"molecular-partners","refs":[]},{"group":"company","date":"2004","precision":"year","title":"Nerviano Medical Sciences founded","note":"Nerviano","from":"nerviano-medical-sciences","refs":[]},{"group":"company","date":"2004","precision":"year","title":"Shanghai Allist Pharmaceuticals founded","note":"Shanghai","from":"allist","refs":[]},{"group":"company","date":"2004","precision":"year","title":"ViewRay (MRIdian) founded","note":"Denver, CO","from":"viewray","refs":[]},{"group":"history","date":"2004","precision":"year","title":"Azacitidine approved","note":"Myelodysplastic syndromes / neoplasms (MDS). First drug approved for MDS (US); AZA-001 (2009) shows survival benefit in higher-risk disease.","from":"mds","refs":["azacitidine"]},{"group":"history","date":"2004","precision":"year","title":"Azacitidine approved (MDS)","note":"Acute myeloid leukaemia. First hypomethylating agent; later the AML backbone for venetoclax and IDH/menin combinations.","from":"aml","refs":["azacitidine"]},{"group":"history","date":"2004","precision":"year","title":"Azacitidine approved for MDS in the United States","note":"Higher-risk myelodysplastic syndromes","from":"mds-higher-risk","refs":["azacitidine"]},{"group":"history","date":"2004","precision":"year","title":"Azacitidine approved for MDS including CMML","note":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","from":"cmml","refs":["azacitidine"]},{"group":"history","date":"2004","precision":"year","title":"Azacitidine approved for myelodysplastic syndromes, then adopted for low-blast AML","note":"Acute myeloid leukaemia in older or unfit patients","from":"aml-older-unfit","refs":["azacitidine"]},{"group":"history","date":"2004","precision":"year","title":"Bernier and Cooper trials: postoperative cisplatin chemoradiation for extranodal extension or positive margins","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":[]},{"group":"history","date":"2004","precision":"year","title":"Bevacizumab and cetuximab approved","note":"Colorectal cancer. First anti-angiogenic and first anti-EGFR antibodies; MOSAIC establishes adjuvant FOLFOX.","from":"colorectal","refs":["bevacizumab","cetuximab","folfox"]},{"group":"history","date":"2004","precision":"year","title":"CAO/ARO/AIO-94: preoperative chemoradiation halves local recurrence","note":"Rectal cancer","from":"rectal-cancer","refs":["cao-aro-aio-94"]},{"group":"history","date":"2004","precision":"year","title":"Cinacalcet approved","note":"Parathyroid carcinoma. Including hypercalcaemia of parathyroid carcinoma (FDA).","from":"parathyroid-carcinoma","refs":[]},{"group":"history","date":"2004","precision":"year","title":"EGFR mutations explain gefitinib responses","note":"Non-small-cell lung cancer. Lynch, Paez, and Pao identify activating EGFR mutations; the birth of lung cancer precision medicine.","from":"nsclc","refs":["egfr","egfr-exon19-l858r"]},{"group":"history","date":"2004","precision":"year","title":"EGFR mutations explain gefitinib responses","note":"Lung cancer (all types)","from":"lung-cancer","refs":["gefitinib"]},{"group":"history","date":"2004","precision":"year","title":"EGFR mutations found to explain gefitinib responses in Boston (Lynch, Paez, Pao)","note":"EGFR-mutated non-small-cell lung cancer","from":"egfr-mutant-nsclc","refs":["gefitinib","thomas-lynch","daniel-haber","egfr"]},{"group":"history","date":"2004","precision":"year","title":"ESPAC-1: adjuvant chemotherapy helps, chemoradiotherapy harms","note":"Pancreatic ductal adenocarcinoma. 289 patients; five-year survival 21 versus 8 percent with chemotherapy, 10 versus 20 percent with chemoradiotherapy.","from":"pancreatic","refs":["paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004"]},{"group":"history","date":"2004","precision":"year","title":"FLIPI prognostic index","note":"Follicular lymphoma","from":"follicular-lymphoma","refs":[]},{"group":"history","date":"2004","precision":"year","title":"Gene-expression classes 1 and 2 predict metastasis (Onken, Harbour)","note":"Uveal melanoma","from":"uveal-melanoma","refs":[]},{"group":"history","date":"2004","precision":"year","title":"Habr-Gama reports watch and wait after complete clinical response in Sao Paulo","note":"Rectal cancer","from":"rectal-cancer","refs":["angelita-habr-gama","organ-preservation"]},{"group":"history","date":"2004","precision":"year","title":"HER2 kinase domain mutations found in lung adenocarcinoma","note":"HER2-mutant non-small-cell lung cancer","from":"her2-mutant-nsclc","refs":["her2"]},{"group":"history","date":"2004","precision":"year","title":"KIT mutations and imatinib responses described in thymic carcinoma","note":"Thymic carcinoma","from":"thymic-carcinoma","refs":["imatinib"]},{"group":"history","date":"2004","precision":"year","title":"MA.17: letrozole after five years of tamoxifen reduces late recurrence","note":"High-risk early HR-positive breast cancer","from":"hr-positive-early-high-risk","refs":["letrozole"]},{"group":"history","date":"2004","precision":"year","title":"More receptor is enough on its own","note":"Prostate cancer. A modest rise in androgen receptor expression, with no mutation, is shown to be necessary and sufficient for antiandrogen resistance and to turn antagonists into a...","from":"prostate","refs":["paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","androgen-receptor"]},{"group":"history","date":"2004","precision":"year","title":"Oncotype DX launched","note":"HR-positive / HER2-negative breast cancer. Gene-expression recurrence score enters practice.","from":"breast-hr-positive","refs":["oncotype-dx"]},{"group":"history","date":"2004","precision":"year","title":"Pemetrexed approved: first mesothelioma drug","note":"Mesothelioma","from":"mesothelioma","refs":["pemetrexed"]},{"group":"history","date":"2004","precision":"year","title":"Pemetrexed-cisplatin approved","note":"Mesothelioma","from":"mesothelioma","refs":[]},{"group":"history","date":"2004","precision":"year","title":"RTOG 9508: radiosurgery boost improves function and, for single lesions, survival","note":"Brain metastases (secondary brain tumours)","from":"secondary-brain-tumours","refs":["radiosurgery-srs"]},{"group":"history","date":"2004","precision":"year","title":"Surveillance for stage I paediatric testicular tumours","note":"Germ cell tumours of childhood and adolescence (extracranial and CNS). POG/CCG intergroup studies show surgery alone is safe for low-stage disease.","from":"paediatric-germ-cell-tumours","refs":[]},{"group":"history","date":"2004","precision":"year","title":"TAX 327: docetaxel is the first drug to lengthen life in castration-resistant disease","note":"Metastatic castration-resistant prostate cancer","from":"prostate-mcrpc","refs":["docetaxel"]},{"group":"history","date":"2004","precision":"year","title":"The first drug to extend survival after hormone therapy fails","note":"Prostate cancer. TAX 327 gave median survival of 18.9 months with three-weekly docetaxel against 16.5 with mitoxantrone, and improved pain and quality of life; SWOG 9916 reported 1...","from":"prostate","refs":["paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004","docetaxel"]},{"group":"history","date":"2004","precision":"year","title":"Two-tier grading separates low-grade from high-grade serous cancer (MD Anderson)","note":"Low-grade serous ovarian cancer","from":"low-grade-serous-ovarian-cancer","refs":[]},{"group":"journal","date":"2004","precision":"year","title":"Cancer genomics & proteomics founded","note":"International Institute of Anticancer Research","from":"cancer-genomics-and-proteomics","refs":[]},{"group":"journal","date":"2004","precision":"year","title":"Experimental oncology founded","note":"Akademperiodyka (National Academy of Sciences of Ukraine)","from":"experimental-oncology","refs":[]},{"group":"journal","date":"2004","precision":"year","title":"Nature Reviews Clinical Oncology founded","note":"Springer Nature","from":"nature-reviews-clinical-oncology","refs":[]},{"group":"journal","date":"2004","precision":"year","title":"Pediatric Blood & Cancer founded","note":"Wiley","from":"pediatric-blood-and-cancer","refs":[]},{"group":"journal","date":"2004","precision":"year","title":"PLOS Medicine founded","note":"Public Library of Science","from":"plos-medicine","refs":[]},{"group":"law","date":"2004","precision":"year","title":"EU data and market protection (8+2+1)","note":"European Union, regulation.","from":"eu-data-exclusivity","refs":[]},{"group":"law","date":"2004","precision":"year","title":"Regulation (EC) No 726/2004: the EU centralised procedure","note":"European Union, regulation.","from":"eu-regulation-726-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","note":"Neoptolemos JP, Stocken DD, Friess H, et al. New England Journal of Medicine.","from":"paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","note":"Lynch TJ, Bell DW, Sordella R, et al. New England Journal of Medicine.","from":"paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Androgen receptor in prostate cancer","note":"Heinlein CA, Chang C. Endocrine reviews.","from":"paper-androgen-receptor-prostate-endocr-rev-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","note":"Cristofanilli M, Budd GT, Ellis MJ, et al. New England Journal of Medicine.","from":"paper-cristofanilli-n-engl-j-med","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Dhebri 2004: diagnosis, treatment and outcome of pancreatoblastoma","note":"Dhebri AR, Connor S, Campbell F, Ghaneh P, Sutton R, Neoptolemos JP. Pancreatology.","from":"paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","note":"Paez JG, Jänne PA, Lee JC, et al. Science.","from":"paper-paez-egfr-mutations-gefitinib-science-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer","note":"Bernier J, Domenge C, Ozsahin M, et al. New England Journal of Medicine.","from":"paper-bernier-eortc-22931-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back","note":"Doll R, Peto R, Boreham J, Sutherland I. BMJ.","from":"paper-doll-peto-50-year-doctors-bmj-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Gallbladder cancer: lessons from a rare tumour","note":"Wistuba II, Gazdar AF. Nature Reviews Cancer.","from":"paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Hurwitz 2004: bevacizumab with chemotherapy for metastatic colorectal cancer, the first anti-angiogenic drug to extend life","note":"Hurwitz H, Fehrenbacher L, Novotny W, et al. New England Journal of Medicine.","from":"paper-hurwitz-bevacizumab-crc-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","note":"Hughes KS, Schnaper LA, Berry D, et al. New England Journal of Medicine.","from":"paper-hughes-n-engl-j-med","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Mesothelin: a new target for immunotherapy","note":"Hassan R, Bera T, Pastan I. Clinical Cancer Research.","from":"paper-mesothelin-mesothelioma-clin-cancer-res-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Molecular determinants of resistance to antiandrogen therapy","note":"Chen CD, Welsbie DS, Tran C, et al. Nature Medicine.","from":"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","note":"Habr-Gama A, Perez RO, Nadalin W, et al. Annals of Surgery.","from":"paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","note":"André T, Boni C, Mounedji-Boudiaf L, et al. New England Journal of Medicine.","from":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma","note":"Cooper JS, Pajak TF, Forastiere AA, et al. New England Journal of Medicine.","from":"paper-cooper-rtog-9501-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Sauer 2004: chemoradiotherapy before rather than after surgery for rectal cancer (CAO/ARO/AIO-94)","note":"Sauer R, Becker H, Hohenberger W, et al. New England Journal of Medicine.","from":"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","note":"De Santis M, Becherer A, Bokemeyer C, et al. Journal of Clinical Oncology.","from":"paper-sempet-de-santis-jco-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Singh 2004: identification of human brain tumour initiating cells","note":"Singh SK, Hawkins C, Clarke ID, et al. Nature.","from":"paper-singh-brain-tumour-initiating-cells-nature-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","note":"Petrylak DP, Tangen CM, Hussain MH, et al. New England Journal of Medicine.","from":"paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","note":"Tannock IF, de Wit R, Berry WR, et al. New England Journal of Medicine.","from":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"The stroma as a crucial target in rat mammary gland carcinogenesis","note":"Maffini MV, Soto AM, Calabro JM, et al. Journal of cell science.","from":"paper-maffini-j-cell-sci","refs":[]},{"group":"paper","date":"2004","precision":"year","title":"Xia 2004: the randomised trial behind China's approval of the oncolytic adenovirus H101","note":"Xia ZJ, Chang JH, Zhang L, et al. Ai Zheng (Chinese Journal of Cancer).","from":"paper-xia-h101-head-neck-aizheng-2004","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"[18F]FLT-PET in oncology: current status and opportunities","note":"European Journal of Nuclear Medicine and Molecular Imaging","from":"lukas-b-been","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?","note":"Journal of Clinical Oncology","from":"lynn-schuchter","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","note":"PNAS","from":"chen-saijuan","refs":["chen-zhu"]},{"group":"person-paper","date":"2004","precision":"year","title":"Anatomy of the nipple and breast ducts revisited","note":"Cancer","from":"susan-love","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base","note":"Cancer","from":"juergen-debus","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Conversion to sirolimus: a successful treatment for posttransplantation Kaposi???s sarcoma12","note":"Transplantation","from":"josep-maria-campistol","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Development of the Proteasome Inhibitor Velcade™ (Bortezomib)","note":"Cancer Investigation","from":"julian-adams","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock","note":"Critical Care Medicine","from":"patrik-rossi","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"DNA double-strand break repair by homologous recombination","note":"Mutat Res","from":"miroslav-chovanec","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327)","note":"NEJM","from":"ian-tannock","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria","note":"Nature","from":"rajesh-gokhale","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Genetic Determinants of Susceptibility to UV Light-Associated Skin Cancer","note":"Exogenous Dermatology","from":"eli-sprecher","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"High frequency of mutations of the PIK3CA gene in human cancers","note":"Science","from":"yardena-samuels","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Is There a Link Between DNA Polymerase Beta and Cancer?","note":"Cell Cycle","from":"joann-sweasy","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Mortality in relation to smoking: 50 years' observations on male British doctors","note":"BMJ","from":"richard-peto","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"NRPS-PKS: a knowledge-based resource for analysis of NRPS/PKS megasynthases","note":"Nucleic Acids Res","from":"rajesh-gokhale","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Outcome and Prognostic Factors of Acute Lymphoblastic Leukemia in Children at the National Cancer Institute, Egypt","note":"Journal of Pediatric Hematology/Oncology","from":"sherif-abouel-naga","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Pericardial synovial sarcoma: 14-year survival with multimodality therapy","note":"The Annals of Thoracic Surgery","from":"paul-herijgers","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasia","note":"Vaccine","from":"ian-frazer","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","note":"International Journal of Radiation Oncology, Biology, Physics","from":"albert-koong","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharynge...","note":"Journal of Clinical Oncology","from":"anthony-chan","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Prevention of cervical cancer through papillomavirus vaccination","note":"Nature Reviews Immunology","from":"ian-frazer","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Risk of thrombosis in patients with malignancy and heparin‐induced thrombocytopenia","note":"American Journal of Hematology","from":"lucie-opatrny","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"The development of proteasome inhibitors as anticancer drugs","note":"Cancer Cell","from":"julian-adams","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Transition from meningeal melanocytoma to primary cerebral melanoma","note":"Journal of Neurosurgery","from":"florian-roser","refs":[]},{"group":"person-paper","date":"2004","precision":"year","title":"Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience","note":"Leukemia","from":"biju-george","refs":[]},{"group":"regulatory","date":"2004","precision":"year","title":"Carboplatin: approval (US)","note":"First generics","from":"carboplatin","refs":[]},{"group":"technology","date":"2004","precision":"year","title":"Anti-angiogenic therapy","note":"First use in humans or first approval, as the technology record states it.","from":"antiangiogenic","refs":[]},{"group":"technology","date":"2004","precision":"year","title":"CellSearch circulating tumour cell count","note":"First use in humans or first approval, as the technology record states it.","from":"cellsearch-ctc-count","refs":[]},{"group":"technology","date":"2004","precision":"year","title":"Circulating tumour cell capture","note":"First use in humans or first approval, as the technology record states it.","from":"ctc-capture","refs":[]},{"group":"trial","date":"2004","precision":"year","title":"AVF2107g reported","note":"Median overall survival 20.3 against 15.6 months, hazard ratio 0.66.","from":"avf2107g","refs":["colorectal","bevacizumab","irinotecan","fluorouracil"]},{"group":"trial","date":"2004","precision":"year","title":"Big Lung Trial reported","note":"In advanced disease, chemotherapy gave a hazard ratio for death of 0.77 and a median gain of nine weeks; in the surgical and radical radiotherapy settings there was no survival ben...","from":"big-lung-trial","refs":["nsclc","lung-cancer","cisplatin"]},{"group":"trial","date":"2004","precision":"year","title":"CALGB 9343 reported","note":"10-year locoregional recurrence 10% (tamoxifen alone) vs 2% (tamoxifen plus radiotherapy); no survival difference.","from":"calgb-9343","refs":["breast-hr-positive","breast-cancer","tamoxifen"]},{"group":"trial","date":"2004","precision":"year","title":"CAO/ARO/AIO-94 (German Rectal Cancer Study) reported","note":"5-year local recurrence 6% (preoperative) vs 13% (postoperative); overall survival unchanged.","from":"cao-aro-aio-94","refs":["colorectal","rectal-cancer","fluorouracil"]},{"group":"trial","date":"2004","precision":"year","title":"Dutch Bone Metastasis Study reported","note":"Pain response to initial treatment 71 percent after a single 8 Gy fraction against 73 percent after 24 Gy in multiple fractions (p=0.84); retreatment raised the single-fraction fig...","from":"dutch-bone-metastasis-study","refs":["nsclc","sclc","lung-cancer"]},{"group":"trial","date":"2004","precision":"year","title":"ESPAC-1 reported","note":"Five-year survival 21 percent with adjuvant chemotherapy against 8 percent without (p 0.009); 10 percent with chemoradiotherapy against 20 percent without (p 0.05).","from":"espac-1","refs":["pancreatic","resectable-pdac","fluorouracil","leucovorin"]},{"group":"trial","date":"2004","precision":"year","title":"IALT (International Adjuvant Lung Cancer Trial) reported","note":"Five-year survival 44.5 against 40.4 percent (hazard ratio for death 0.86).","from":"ialt","refs":["resectable-nsclc","cisplatin","etoposide","vinorelbine"]},{"group":"trial","date":"2004","precision":"year","title":"MOSAIC reported","note":"Three-year disease-free survival 78.2 against 72.9 percent (hazard ratio 0.77); six-year overall survival benefit in stage III only.","from":"mosaic","refs":["colorectal","colon-cancer","folfox","oxaliplatin"]},{"group":"trial","date":"2004","precision":"year","title":"SWOG 9916 reported","note":"Median overall survival 17.5 against 15.6 months (hazard ratio for death 0.80, 95 percent confidence interval 0.67 to 0.97, p=0.02) and time to progression 6.3 against 3.2 months...","from":"swog-9916","refs":["prostate","prostate-mcrpc","docetaxel","estramustine"]},{"group":"trial","date":"2004","precision":"year","title":"TAX 327 reported","note":"Median survival 18.9 months with three-weekly docetaxel against 16.5 months with mitoxantrone (hazard ratio for death 0.76, 95 percent confidence interval 0.62 to 0.94, p=0.009), w...","from":"tax-327","refs":["prostate","prostate-mcrpc","docetaxel","mitoxantrone"]},{"group":"regulatory","date":"2004-01","precision":"month","title":"Oncotype DX: filing (US)","note":"Launched as a laboratory-developed test","from":"oncotype-dx","refs":[]},{"group":"regulatory","date":"2004-02","precision":"month","title":"Bevacizumab: approval (US)","note":"First anti-angiogenic approval (AVF2107)","from":"bevacizumab","refs":[]},{"group":"regulatory","date":"2004-02","precision":"month","title":"Cetuximab: approval (US)","note":"Initial approval in EGFR-expressing mCRC (BOND trial)","from":"cetuximab","refs":[]},{"group":"regulatory","date":"2004-05-19","precision":"day","title":"Azacitidine: approval (US)","note":"First hypomethylating agent approved (MDS)","from":"azacitidine","refs":[]}]},"route":"/years/2004/","neighbours":{"year":[{"id":"2003","kind":"year","name":"2003 in oncology","route":"/years/2003/"},{"id":"2005","kind":"year","name":"2005 in oncology","route":"/years/2005/"}]}}